"The voice for cancer physicians and their patients in Massachusetts."

FDA approves zanubrutinib for Waldenström’s macroglobulinemia

31 Aug 2021 3:22 PM | Katy Monaco (Administrator)
Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström’s macroglobulinemia (WM).  Press ReleaseAugust 31, 2021.  More information.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software